Pharma Research Library | Pharma Info Index Research | Innovation | Opportunities |
Y. Suresh*1, Sanjay Kumar Jain2
1Safa College of Pharmacy, Kurnool, Andhra Pradesh, India
2Department of Pharmaceutical Analysis, Bundelkhand University, Jhansi, U.P, India
A B S T R A C T
The aim of present research work to develop and validated RP-HPLC method for the simultaneous estimation Durnavir and Ritonavir in bulk and pharmaceutical dosage form. The chromatographic separation was achieved on Inertsil ODS (4.6 x 100mm, 5mm) column and maintained flow rate was 1.0 ml/min. The injection volume was 20 ml. Detection of absorption maxima was monitored at 220 nm. The optimized mobile phase was consisting of phosphate buffer pH 3.5 and acetonitrile + Methanol in the ratio of 30:70 %v/v. The linearity over to the obtained concentrations from 120-600 ppm for Durnavir and 20-100ppm for Ritonavir with correlation coefficient was found to be not more than 0.999 for both drugs. In precision studies % RSD was found to be less than 2%. The mean percentage recovery was found to be 100.86 % for Durnavir and 99.58% for Ritonavir. All the validation parameters results were found to be within the limit. So the developed method can be suggest. that routine quality control analysis of Durnavir and Ritonavir in analytical laboratories.
Keywords: Durnavir, Ritonavir, RP-HPLC, Mobile phase, Validation
